Home / Pharmaceuticals / Breast Cancer Treatment Market By Drug Type (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor Antagonists) - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022

Breast Cancer Treatment Market By Drug Type (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor Antagonists) - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022

Published: Jun 2016 | Report Code: 57921-06-16

This report on global breast cancer treatment market studies various drugs used for treatment of breast cancer along with pipeline analysis of upcoming potential drugs.  Breast cancer is the second most common cancer observed in women worldwide, accounting for around 17% of all female cancers, making the disease exceptionally prevalent. The predictions shared by GLOBOCON in 2012 suggests that the incidence rate of breast cancer in 2012 was for ages<65 was 1.16 Mn and ages >= 65 was 503, 158 and by 2020 it is anticipated that ages<65 will be 1.33 Mn and ages >=65 will be 643,442. Thus, rising incidences of breast cancer and mounting social awareness in developed and developing countries is assisting the market growth throughout the forecast period.

For the purpose of this study, the various drugs classes studied include HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptor. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for breast cancer treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global breast cancer treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Breast Cancer Treatment Market
 

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Breast Cancer Treatment Market Portaiture
2.2 Global Breast Cancer Treatment Market Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Breast Cancer Treatment : Market Dynamics and Outlook
3.1 Breast Cancer Treatment Market Overview
3.2 Breast Cancer Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)

Chapter 4 Global Breast Cancer Treatment Market, By Type of Drug Class
4.1 Preface
4.2 HER2 Inhibitors
4.2.1 Trastuzumab
4.2.2 Pertuzumab
4.2.3 Ado-trastuzumab emtansine
4.2.4 Lapatinib
4.3 Mitotic Inhibitors
4.3.1 Eribulin
4.3.2 Docetaxel
4.3.3 Ixabepilone
4.4 Anti-metabolites
4.4.1 Gemcitabine
4.5 Aromatase Inhibitors
4.5.1 Leterozole
4.5.2 Exemestane
4.5.3 Anastrozole
4.5.4 Palbociclib
4.5.5 Everolimus
4.6 Hormone Receptor Antagonists
4.6.1 Goserelin Acetate
4.6.2 Fulvestrant
4.6.3 Toremifene
4.7 Pipeline Analysis
4.7.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.7.1.1 Abemaciclib
4.7.1.2 Buparlisib
4.7.1.3 NeuVax
4.7.1.4 Niraparib
4.7.1.5 Lynparza
4.7.1.6 Veliparib
4.7.1.7 Neratinib
4.7.1.8 Ribociclib
4.7.1.9 Others
4.7.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Breast Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Eisai Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Eli Lilly and Company
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 GlaxoSmithKline plc
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Novartis International AG
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Pfizer, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Puma Biotechnology, Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Sanofi S.A.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Teva Pharmaceutical Industries Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG. 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Breast Cancer Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Breast Cancer Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Breast Cancer Treatment Market, 2015 (Value %)
FIG. 5 Global Trastuzumab Market, 2013 – 2022 (USD Mn)
FIG. 6 Global Pertuzumab Market, 20137– 2022 (USD Mn)
FIG. 7 Global Ado-trastuzumab Emtansine Market, 2013 –2022 (USD Mn)
FIG. 8 Global Lapatinib Market, 2013 – 2022 (USD Mn)
FIG. 9 Global Eribulin Market, 20137– 2022 (USD Mn)
FIG. 10 Global Docetaxel Market, 2013 –2022 (USD Mn)
FIG. 11 Global Ixabepilone Market, 2013 – 2022 (USD Mn)
FIG. 12 Global Gemcitabine Market, 2013– 2022 (USD Mn)
FIG. 13 Global Leterozole Market, 2013 –2022 (USD Mn)
FIG. 14 Global Exemestane Market, 2013 –2022 (USD Mn)
FIG. 15 Global Anastrozole Market, 2013 –2022 (USD Mn)
FIG. 16 Global Palbociclib Market, 2013 –2022 (USD Mn)
FIG. 17 Global Everolimus Market, 2013 –2022 (USD Mn)
FIG. 18 Pipeline Analysis: Global Abemaciclib Market, Upto 2022 (USD Mn)
FIG. 19 Pipeline Analysis: Global Buparlisib Market, Upto 2022 (USD Mn)
FIG. 20 Pipeline Analysis: Global NeuVax Market, Upto 2022 (USD Mn)
FIG. 21 Pipeline Analysis: Global Niraparib Market , Upto 2022 (USD Mn)
FIG. 22 Pipeline Analysis: Global Lynparza Market, Upto 2022 (USD Mn)
FIG. 23 Pipeline Analysis: Global Veliparib Market, Upto 2022 (USD Mn)
FIG. 24 Pipeline Analysis: Global Neratinib Market, Upto 2022 (USD Mn)
FIG. 25 Pipeline Analysis: Global Ribociclib Market, Upto 2022 (USD Mn)
FIG. 26 Global U.S.Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 27 Global Canada Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 28 Global U.K Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 29 Global Germany Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 30 Global Rest of Europe Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 31 Global China Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 32 Global Japan Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 33 Global Rest of Asia Pacific Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 34 Global Brazil Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 35 Global Mexico Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 36 Global Rest of the Latin America Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)
FIG. 37 Global Middle East and Africa Breast Cancer Treatment Market, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Breast Cancer Treatment Market, by Type of Drug Class, 2013 – 2022 (USD Mn)
TABLE 2 Global Breast Cancer Treatment Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 Global HER 2 Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 4 Global Mitotic Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 5 Global Aromatase Inhibitors Market, 2013 – 2022 (USD Mn)
TABLE 6 Global Hormone Receptor Antagonists Market, 2013 – 2022 (USD Mn)
TABLE 7 North America Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 8 Europe Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 9 Asia – Pacific Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)
TABLE 10 Latin America Breast Cancer Treatment Market, by Country, 2013 – 2022 (USD Mn)

Breast cancer is hormone related disorder and the factors that transform the risk of this cancer when diagnosed premenopausally and when diagnosed (much more commonly) postmenopausally are not the same. According to World Cancer Research Fund International, breast cancer is the most common cancer in women worldwide with nearly 1.7 million new cases diagnosed in 2012.This represents about 12% of all new cancer cases and 25% of all cancers in women.  The therapeutic treatment of breast cancer ranges from regular regimens to biological drugs. Market experts suggest that overall the market is experiencing significant growth driven by rising awareness among the population and efficient drug therapies being introduced by pharmaceutical manufacturers. In addition to that, accelerated approvals have been observed for drugs against breast cancer, which is providing momentum for breast cancer research and shifting the equilibrium toward research and development of novel therapies with minimum side effects and maximum efficiency against breast cancer treatment.

Based on the type of drug class, the breast cancer treatment market is segmented into:

  • HER2 Inhibitors
    • Trastuzumab
    • Pertuzumab
    • Ado-trastuzumab emtansine
    • Lapatinib
  • Mitotic Inhibitors
    • Eribulin
    • Docetaxel
    • Ixabepilone
  • Anti-metabolites
    • Gemcitabine
  • Aromatase Inhibitors
    • Leterozole
    • Exemestane
    • Anastrozole
    • Palbociclib
    • Everolimus
  • Hormone Receptor Antagonists
    • Goserelin Acetate
    • Fulvestrant
    • Toremifene

Breast Cancer Treatment Market

The major classes of drugs for breast cancer are HER2 inhibitors, anti-metabolites, aromatase inhibitors, mitotic inhibitors, and hormone receptors antagonists. In base year 2015, HER 2 inhibitors segment accounted for the major share of the breast cancer treatment market. The key factors assisting the growth of this segment are premium cost, efficient treatment, less side effects, and supported and recommended by several non-governmental and globally acknowledged organizations. Targeted therapies have been treatment of choice in most of the parts of the world because targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as a protein that allows the cancer cells to grow in a rapid or abnormal way, and less likely than chemotherapy to harm normal, healthy cells.       

For the purpose of this study, the global breast cancer treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Breast Cancer Treatment Market

In base year 2015, North America and Europe dominated the market with around 60.7% of the overall market share. The key factors assisting the growth of breast cancer treatment market in these regions are increasing social awareness related to diagnosis and treatment of breast cancer, rising prevalence of breast cancer and advanced healthcare infrastructure along with supportive reimbursement policies. Market experts suggest that, as North American and European markets are the most lucrative pharmaceutical markets key breast cancer treatment drugs are initially approved in these regions. The upcoming pipeline drugs are expected to play crucial role in the breast cancer treatment market where early market entry and high drug prices would be the key factors that will boost the overall breast cancer treatment market in North America and Europe initially. On the other hand, Asia-Pacific breast cancer treatment is anticipated to experience significant growth throughout the forecast period 2016 – 2022. In base year 2015, Japan was observed as the leading market followed by China and India. India and China have a large low- and middle-income population; hence, demand for low cost treatments will be high. However, in case of life threatening diseases such as breast cancer the market scenario is expected to be different as the available and upcoming treatments are more efficient and premium.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients